- cafead Jul 30, 2020 at 11:02: AM
via Phase III advance trial data for AbbVie’s migraine prevention drug atogepant look good — but are the results good enough to rival Biohaven’s two-in-one treatment and prevention drug, rimegepant, sold as Nurtec?
AbbVie picked up atogepant from Allergan in a $63 billion buyout last year. It also claimed the Botox franchise and $16 billion in annual revenue.
article source
AbbVie picked up atogepant from Allergan in a $63 billion buyout last year. It also claimed the Botox franchise and $16 billion in annual revenue.
article source